Meletios Therapeutics

Description

Meletios Therapeutics is a French biotech offering highly innovative broad-spectrum therapeutic approaches to treat viral infections. Meletios develops a proprietary platform for new RNA biologics, Defective Interfering RNA (DI-RNA) and a host targeting agent, MLT103. DI-RNAs are RNA sequences wich both act on interfering on viral replication and activating innate immunity. Candidates are under development for arboviruses (Dengue, Zika, Chikungunya). This platform enables the generation of DI-RNAs within months only on any RNA virus. MLT103 is an oral small molecule targeting key host proteins involved in cholesterol metabolism. MLT103 successfully demonstrated immunomodulatory properties, targeting respiratory viruses and is currently preparing for Human proof of concept.

Company members

Catherine Martre - CEO

HealthTech Innovation Days - 6th edition is an event organized by HealthTech For Care.

HealthTech For Care is an endowment fund (non-for profit organization) whose primary mission is to advocate for universal access to healthcare for all European patients, with a specific focus on advanced medical technologies and innovative drugs. The fund's initiatives and events with a European dimension gather all stakeholders involved in the health innovation value chain, fostering better coordination within the European health ecosystem. HealthTech For Care is administered by a board of European experts.

For any request: contact@htfc-eu.com
Where to find us? Healthtech For Care, 10 Place de Catalogne, 75014 Paris

Meletios Therapeutics

Description

Company members

© HealthTech For Care 2022-2024 - All rights reserved

Cookies Policy

Legal notice

Privacy Policy